Kumar, A., Casulo, C., Advani, R. H., Budde, E., Barr, P. M., Batlevi, C. L., Caron, P., Constine, L. S., Dandapani, S. V., Drill, E., Drullinsky, P., Friedberg, J. W., Grieve, C., Hamilton, A., Hamlin, P. A., Hoppe, R. T., Horwitz, S. M., Joseph, A., Khan, N., Laraque, L., Matasar, M. J., Moskowitz, A. J., Noy, A., Palomba, M. L., Schöder, H., Straus, D. J., Vemuri, S., Yang, J., Younes, A., Zelenetz, A. D., Yahalom, J., & Moskowitz, C. H. (2021). brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma. Journal of clinical oncology, 39(20), 2257–2265. http://access.bl.uk/ark:/81055/vdc_100150610394.0x00003b